STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER:	(X2) MULTIPLE CONSTRUCTION	(X3) DATE SURVEY COMPLETED
	0011378	A. BUILDING: _____ B. WING _____	R 08/06/2025

NAME OF PROVIDER OR SUPPLIER	STREET ADDRESS, CITY, STATE, ZIP CODE
KELLOGG	1947 DUPONT DR JANESVILLE, WI 53546

(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (EACH DEFICIENCY MUST BE PRECEDED BY FULL REGULATORY OR LSC IDENTIFYING INFORMATION)	ID PREFIX TAG	PROVIDER'S PLAN OF CORRECTION (EACH CORRECTIVE ACTION SHOULD BE CROSS-REFERENCED TO THE APPROPRIATE DEFICIENCY)	(X5) COMPLETE DATE
{N 000}	Initial Comments On 08/01/2025, with information gathered through 08/06/2025, Surveyor conducted a verification visit at Kellogg. One deficiency was identified. One of one deficiency was a repeat violation (see Statement of Deficiency (SOD) 813I11). Under statutory provisions of Wis. Stat. Ch. 50, a $200 revisit fee is being assessed. Census: 4	{N 000}		
{N 432}	83.38(1)(h) Medication administration. As appropriate, the CBRF shall teach residents the necessary skills to achieve and maintain the resident ' s highest level of functioning. In addition to the assessed needs as determined under s. DHS 83.35(1), the CBRF shall provide or arrange services adequate to meet the needs of the residents in all of the following areas: Medication administration. The CBRF shall provide medication administration appropriate to the resident ' s needs. This Rule is not met as evidenced by: Based on observation, record review and interview, the provider did not ensure 1 of 3 residents received prescribed medications prior to expiration dates. This is a repeat deficiency. See Statement of Deficiency (SOD) 813I11, dated 05/28/2025. Resident 2's Fluticasone (nasal spray), with dispensed dates of 01/04/2025 and 03/24/2025,	{N 432}		

LABORATORY DIRECTOR'S OR PROVIDER/SUPPLIER REPRESENTATIVE'S SIGNATURE | TITLE | (X6) DATE

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER:	(X2) MULTIPLE CONSTRUCTION	(X3) DATE SURVEY COMPLETED
	0011378	A. BUILDING: _____ B. WING _____	R 08/06/2025

NAME OF PROVIDER OR SUPPLIER	STREET ADDRESS, CITY, STATE, ZIP CODE
KELLOGG	1947 DUPONT DR JANESVILLE, WI 53546

(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (EACH DEFICIENCY MUST BE PRECEDED BY FULL REGULATORY OR LSC IDENTIFYING INFORMATION)	ID PREFIX TAG	PROVIDER'S PLAN OF CORRECTION (EACH CORRECTIVE ACTION SHOULD BE CROSS-REFERENCED TO THE APPROPRIATE DEFICIENCY)	(X5) COMPLETE DATE
{N 432}	Continued From page 1	{N 432}		

was not administered as prescribed.
Resident 2's Loteprednol (eye drops) were dispensed after medication expiration due to being opened.

Findings include:

On 08/01/2025, at approximately 5:25 PM, Surveyor observed the medication cart with Resident Assistant B and Surveyor observed Resident 2's opened bottles of Fluticasone, with dispensed dates of 01/04/2025 and 03/24/2025, and an opened bottle of Loteprednol Etabonate (eye drop), with a dispensed date of 01/06/2025, with a handwritten open date of 05/28/2025.

Resident 2's Medication Administration Records (MARs), dated 07/01/2025 to 08/01/2025, documented:
"Fluticasone Prop 50 MCG (micrograms) spray - Inhale 2 sprays in each nostril once daily."
"Loteprednol Etabonate 0.5% - Install one drop into left eye every morning. Scheduled at 7:00 AM. Start Date: 09/24/2022."

Medications were documented as administered at all opportunities.

Resident 2's 2025 pharmacy delivery reports documented that the Fluticasone was delivered on 01/06/2025 and 03/24/2025.

"Each bottle contains a net fill weight of 16 g (grams) and will provide 120 actuations. Each actuation delivers 50 mcg (micrograms) of fluticasone propionate in 100 mg (milligram) of formulation through the nasal adapter. The correct amount of medication in each spray cannot be assured after 120 sprays even though the bottle is not completely empty." (Source:

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER:	(X2) MULTIPLE CONSTRUCTION	(X3) DATE SURVEY COMPLETED
	0011378	A. BUILDING: _____ B. WING _____	R 08/06/2025

NAME OF PROVIDER OR SUPPLIER	STREET ADDRESS, CITY, STATE, ZIP CODE
KELLOGG	1947 DUPONT DR JANESVILLE, WI 53546

(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (EACH DEFICIENCY MUST BE PRECEDED BY FULL REGULATORY OR LSC IDENTIFYING INFORMATION)	ID PREFIX TAG	PROVIDER'S PLAN OF CORRECTION (EACH CORRECTIVE ACTION SHOULD BE CROSS-REFERENCED TO THE APPROPRIATE DEFICIENCY)	(X5) COMPLETE DATE
{N 432}	Continued From page 2 National Institute of Health website, Fluticasone Propionate, 12/2022, https://dailymed.nlm.nih.gov/dailymed/fda (retrieval date - May 26, 2025).) Surveyor determined Resident 2's bottle of Fluticasone would last approximately 30 days (120 divided by 2 sprays x each nostril = 4, 120 divided by 4 = 30). "Do not use this medicine after the expiry date which is stated on the carton and bottle after expiry. The expiry date refers to the last day of that month. Throw away any solution 28 days after opening." (Electronic Medicines Compendium website, Lotemax [Loteprednol Etabonate] 0.5% w/v Eye Drops, Suspension, October 2022, https://www.medicines.org.uk/emc/product/6212/pil#gref (retrieval date - May 28, 2025).) Surveyor determined Resident 2's bottle of Loteprednol Etabonate should have been disposed of approximately 06/28/2025. On 08/05/2025 at 4:15, Surveyor emailed Program Director B and explained his/her observation of Resident 2's Fluticasone and Loteprednol Etabonate. On 08/06/2025 at 8:28 AM, Program Director B emailed Surveyor and stated they were working with the pharmacy to determine parameters when liquids, creams and drops expired after opening.	{N 432}		